


CLAIMS


We claim:

- 5 1. A compound of Formula I



wherein:

- 10 A is hydrogen, C₁₋₄alkyl, C₁₋₄aminoalkyl, or a heterocycle selected from the group consisting



W is NR³, O, or S;

- 15 R¹ is selected from phenyl, naphthyl, benzfuranyl, benzthienyl, and indolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkyl, alkyloxy, cyano, trifluoromethyl, and alkoxy carbonyl;

R² is C₁₋₆alkyl or C₃₋₇cycloalkyl;

20

R³ is hydrogen or C₁₋₆alkyl;

m is 0, 1, 2, or 3;

25 n is 1 or 2;

X is CO or SO₂;


- 30 B is selected from C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylmethyl; C₁₋₃methoxyalkyl, and C₁₋₃phenoxyalkyl or is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, benzfuranyl, benzthienyl, indolyl,

benzoxazolyl, and indazolyl moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxy, trifluoromethyl, cyano, and $-N(R^3)_2$;

or a pharmaceutically acceptable salt or solvate.


5

2. A compound of claim 1 where the carbon marked with an asterisk is of the (R) stereochemistry.



10

3. A compound of claim 1 where A is C_{1-4} aminoalkyl, or a heterocycle selected from



4. A compound of claim 1 where m is 1 and R^1 is phenyl substituted with 1-2 substituents selected from halo, alkyl, alkyloxy, cyano, carboalkoxy.


5. A compound of claim 1 where X is CO and B is selected from C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkylmethyl, C_{1-3} methoxyalkyl, and C_{1-3} phenoxyalkyl or is selected from phenyl, pyrazinyl, furanyl, isoxazolyl, and benzthienyl, moieties that are unsubstituted or substituted with 1 to 2 substituents selected from halo, alkoxy, hydroxy, trifluoromethyl, cyano, and $-N(R^3)_2$.

6. A compound of claim 1 where n is 1.

25 7. The compound of claim 7: $N-[1-[(2R)-3-(4-Chlorophenyl)-2-[[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-azetidinyl]-N-cyclohexyl-3-methyl-butanamide$.

8. A compound of claim 1 where n is 2.

30 9. A compound of claim 8 where the carbon marked with an asterisk is of the (S) stereochemistry.



10. A compound of claim 9 selected from the following group:

- 5 (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;
- (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;
- 10 (2S)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(1-oxopentyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;
- (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(2-furanylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide;
- 15 N-[1-[(2R)-3-(4-Chlorophenyl)-2-[(3S)-[3-(dimethylamino)-1-oxopropyl]amino]-1-oxopropyl]-3-pyrrolidinyl]-N-cyclohexyl-3-methyl-butanamide; and
- 20 (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[(3S)-3-[cyclohexyl(methylsulfonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide.

11. A pharmaceutical composition comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

25

12. A method for treating a patient afflicted with a condition responsive to the modulation of melanocortin receptors comprising administration of a therapeutically effective amount of a compound of claim 1.